Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8168734 | 0.87 | CYP4A11 (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9950445 | 0.83 | CDK8 (0.59) | CA1CA2CA12CA9CDK8 | |
| SCHEMBL6644162 | 0.81 | EGFR (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL20590835 | 0.81 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28872504 | 0.81 | KMT2A (0.38) | CA12CA9CDK8CREBBPKDM4E | |
| SCHEMBL2969266 | 0.80 | CA12 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7853544 | 0.79 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11706244 | 0.78 | SLC2A1 (0.46) | CA12CA9CDK8MAPTMEN1 | |
| SCHEMBL13729839 | 0.77 | HDAC8 (0.47) | CA12CA9CDK8TSHRHPGD | |
| SCHEMBL1255885 | 0.75 | MEN1 (0.56) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | claimed |
| CN-102015684-A | Bi-pyridylpyridones as melanin concentrating hormone receptor 1 antagonists | GLAXO GROUP LTD | 2011-04-13 | — | — | CN | claimed |
| JP-57082391-A | — | — | None | — | — | JP | disclosed |
| WO-2026103887-A1 | PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京康辰药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12606548-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4685143-A1 | DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF | Vivozon,Inc. (KR) | 2026-01-28 | — | — | EP | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024196136-A1 | DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF | 주식회사 비보존 | 2024-09-26 | — | — | WO | disclosed |
| US-6093737-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1003374-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1003374-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1998028980-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5296492-A | Certain chroman derivatives useful for treating symptoms caused by contraction of smooth muscles, circulatory diseases or epilepsy | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0518342-A1 | Chroman derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-4968803-A | FLUORINE AS OXIDANT | ALLIED-SIGNAL INC. (US) | 1990-11-06 | — | — | US | disclosed |
| JP-S5782391-A | THIOPYRANO(4,5-B)PYRIDIN-2-ONE DERIVATIVE | OTSUKA PHARMACEUT FACTORY INC | 1982-05-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606548-B2 | Fungicidal oxadiazoles | AOC2, AOC3, MT-CO3 | CA1 2132/4885CA2 306/4885CA12 2402/4885 |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | CA1 4875/4885CA2 3679/4885CA12 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.